Eliza review – an ambitious, unsettling play about the birth of AI48m ago Reviewing my LessWrong post history with Claude1h ago Low-Background Minds1h ago Report: Anthropic targets pre-Thanksgiving IPO launch, despite warning of AI’s ‘existential risks’1h ago Your AI Agents Can Write Code. Can They Understand Your Business?2h ago Meta open sources code to let you make Muse AI gadgets2h ago Robotics AI developer FieldAI reportedly raising $700M in funding2h ago Japan's entertainment robots diversify with AI, offer comfort3h ago OpenAI safety leader David Robinson resigns as the team's upheaval mounts4h ago Apple to Tighten Mac Data Controls in Guard Against AI Agents4h ago Contest-Winning Microscope Video Is Full of AI Confabulations, Scientists Say4h ago The Mulleted, Meme-Loving Billionaire Behind Meta’s Hit AI App4h ago What is recursive self-improvement and what would it mean to ban it?4h ago Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration4h ago

Eliza review – an ambitious, unsettling play about the birth of AI48m ago Reviewing my LessWrong post history with Claude1h ago Low-Background Minds1h ago Report: Anthropic targets pre-Thanksgiving IPO launch, despite warning of AI’s ‘existential risks’1h ago Your AI Agents Can Write Code. Can They Understand Your Business?2h ago Meta open sources code to let you make Muse AI gadgets2h ago Robotics AI developer FieldAI reportedly raising $700M in funding2h ago Japan's entertainment robots diversify with AI, offer comfort3h ago OpenAI safety leader David Robinson resigns as the team's upheaval mounts4h ago Apple to Tighten Mac Data Controls in Guard Against AI Agents4h ago Contest-Winning Microscope Video Is Full of AI Confabulations, Scientists Say4h ago The Mulleted, Meme-Loving Billionaire Behind Meta’s Hit AI App4h ago What is recursive self-improvement and what would it mean to ban it?4h ago Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration4h ago

OpenEvidence Confirms It Has Raised An Additional $250 Million At A $15 Billion Valuation

ForbesPublished 2 days ago

Read the full article

OpenEvidence, an AI-powered clinical decision support tool, has secured an additional $250 million in funding, reaching a valuation of $15 billion. This investment underscores the growing financial interest in AI applications within healthcare.

More on this story

The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding round
8d· Business Insider

#clinical-decision-support #openevidence

More in Healthcare

Healthcare6 min read

How AI Assistants Get Paid Will Decide Whether They Help Or Harm Patients

Forbes13h ago

Healthcare5 min read

The AI Chatbots That Tech Companies Are Aggressively Pushing to Billions of Users Appear to Be Causing Serious Psychological Harms, New Research Finds

Futurism14h ago

The Quest to Quiet Hospital Alarms

The Wall Street Journal11h ago